Trials / Completed
CompletedNCT01164696
A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin
A Prospective Observational Study to Evaluate Quality of Life and Costs in a Real Life Setting in Patients Treated With 90Y-Zevalin
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to compare hematological toxicity, costs, health-related quality of Life (HR-QOL) and outcomes observed in real life in the Belgian Non-Hodgkin Lymphoma (NHL) population receiving 90Y-Zevalin, with model-predicted data at reimbursement on the basis of a clinical trial in heavily pre-treated NHL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128) | Zevalin was administered according to the directives in the approved package leaflet. |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2009-05-01
- Completion
- 2009-05-01
- First posted
- 2010-07-19
- Last updated
- 2010-08-24
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT01164696. Inclusion in this directory is not an endorsement.